Nascent Biotech, Inc. (OTCMKTS:NBIO) Short Interest Update

Nascent Biotech, Inc. (OTCMKTS:NBIO) was the target of a significant increase in short interest in the month of January. As of January 15th, there was short interest totalling 16,500 shares, an increase of 16,400.0% from the December 31st total of 100 shares. Based on an average daily trading volume, of 293,000 shares, the days-to-cover ratio is currently 0.1 days.

Nascent Biotech Stock Performance

Nascent Biotech stock remained flat at $0.00 during midday trading on Friday. Nascent Biotech has a 12 month low of $0.00 and a 12 month high of $0.19. The business has a 50 day simple moving average of $0.04 and a 200-day simple moving average of $0.05.

About Nascent Biotech

Nascent Biotech, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer.